The mechanisms of action of some inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), block PD-1, as shown in Figure 3, preventing it from binding to its ligands and, thus, restoring T cell activity against melanoma cells [191]. Here, PDCD1 is linked to melanoma.